文献速递脑血管病认知障碍与痴呆

吡格列酮使用与糖尿病合并缺血性卒中病史患者痴呆风险降低的关系

Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
PubMed 文献 · Neurology · 2023-02-15

基于韩国国民健康保险服务糖尿病队列(2002-2017)的新发2型糖尿病患者纵向数据,吡格列酮使用与痴呆风险降低相关(aHR=0.84,95%CI 0.75-0.95),在糖尿病发病前有缺血性心脏病或卒中史者中风险降低更明显(aHR分别为0.46和0.57),但观察期间发生卒中时未见痴呆风险降低(aHR=1.27,95%CI 0.80-2.04)。

要点

  • 吡格列酮使用与痴呆风险降低相关(aHR=0.84,95%CI 0.75-0.95)。
  • 糖尿病发病前有卒中史者使用吡格列酮痴呆风险降低更明显(aHR=0.57)。
  • 使用吡格列酮期间发生卒中者未见痴呆风险降低(aHR=1.27)。

核心结论

  • 吡格列酮使用与糖尿病患者痴呆风险降低相关,尤其在糖尿病发病前有卒中或心肌梗死病史者中更明显,提示个体化选择吡格列酮以抑制痴呆的可能性。

研究设计与样本

  • 基于韩国国民健康保险服务糖尿病队列(2002-2017)的全国纵向数据,纳入新发2型糖尿病患者,分析吡格列酮使用与痴呆发病的关联,并用多状态模型评估卒中事件对关联的影响。

主要发现

  • 与不使用吡格列酮相比,使用吡格列酮者痴呆风险降低(aHR=0.84,95%CI 0.75-0.95)。
  • 糖尿病发病前有心肌梗死病史者使用吡格列酮痴呆风险aHR=0.46(95%CI 0.24-0.90),有卒中病史者aHR=0.57(95%CI 0.38-0.86)。
  • 吡格列酮使用与卒中发生率降低相关(aHR=0.81,95%CI 0.66-1.00)。
  • 使用吡格列酮观察期间发生卒中者,痴呆风险未见降低(aHR=1.27,95%CI 0.80-2.04)。

临床怎么用

  • 作者认为,在糖尿病患者中选择吡格列酮以抑制痴呆时,可考虑个体化方法,尤其对糖尿病发病前有卒中或心肌梗死病史者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Previous studies have reported the protective effect of pioglitazone on dementia in patients with type 2 diabetes mellitus (DM). Recent studies have shown that pioglitazone also lowers the risk of primary and recurrent stroke. Understanding the characteristics of patients particularly associated with the benefits of pioglitazone would facilitate its personalized use by specifying subpopulations during routine clinical care. The aim of this study was to examine the effects of pioglitazone use on dementia in consideration of stroke occurrence. METHODS: Using nationwide longitudinal data of patients with DM from the Korean National Health Insurance Service DM cohort (2002-2017), we investigated the association of pioglitazone use with incident dementia in patients with new-onset type 2 DM. The heterogeneity of the treatment effect was examined using exploratory analyses. Using a multistate model, we assessed the extent to which incident stroke affects the association between pioglitazone use and dementia. RESULTS: Pioglitazone use was associated with a reduced risk of dementia, compared with nonuse (adjusted hazard ratio [aHR] = 0.84, 95% CI 0.75-0.95); the risk reduction in dementia was greater among patients with a history of ischemic heart disease or stroke before DM onset (aHR = 0.46, 95% CI 0.24-0.90; aHR = 0.57, 95% CI 0.38-0.86, respectively). The incidence of stroke was also reduced by pioglitazone use (aHR = 0.81, 95% CI 0.66-1.00). However, when the stroke developed during the observation period of pioglitazone use, such lowered risk of dementia was not observed (aHR = 1.27, 95% CI 0.80-2.04). DISCUSSION: Pioglitazone use is associated with a lower risk of dementia in patients with DM, particularly in those with a history of stroke or ischemic heart disease, suggesting the possibility of applying a personalized approach when choosing pioglitazone to suppress dementia in patients with DM.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ha J, Choi DW, Kim KJ, et al. Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke. Neurology. 2023. PMID: 36792375. doi:10.1212/WNL.0000000000207069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。